Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00000886
Status:
COMPLETED
Last Update Posted:
2021-10-29
First Post:
1999-11-02
Brief Title:
A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate IFA
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Conditions & Keywords Data
Conditions:
| Name |
|---|
| HIV Infections |
Keywords:
| Name | View |
|---|---|
| HIV Preventive Vaccine | View |
| HIV Antibodies | View |
| HIV Envelope Protein gp120 | View |
| Drug Carriers | View |
| Hypersensitivity Delayed | View |
| AIDS Vaccines | View |
| CD4-Positive T-Lymphocytes | View |
| CD8-Positive T-Lymphocytes | View |
| HIV Seronegativity | View |
| Neutralization Tests | View |
| Mineral Oil | View |
| Oleic Acids | View |
| Mannose | View |
| HLA-B7 Antigen | View |
| HLA-A2 Antigen | View |